Sirna and Lilly Collaborate to Find RNAi-Based Cancer Therapeutics | GenomeWeb

NEW YORK, Jan. 27 (GenomeWeb News) - Sirna Therapeutics and Eli Lilly plan to develop RNAi therapeutics for cancer, the companies said today.


During the eighteen-month collaboration, the companies will test Sirna's small interfering RNAs against oncology targets from Lilly.


Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: variation patterns in wheat lines, regulatory variation in Capsella grandiflora, and more.

A Rockefeller University researcher is using edited ants to explore complex biological systems, the New York Times writes.

There's a heritable aspect to how much time people spend online, the Los Angeles Times reports.

Stat News reports that Joseph Gulfo is another contender for FDA commissioner.